STOCK TITAN
  1. Home
  2. News
  3. PRGO

Perrigo Company plc - PRGO STOCK NEWS

Welcome to our dedicated news page for Perrigo Company plc (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on Perrigo Company plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Perrigo Company plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Perrigo Company plc's position in the market.

News
Opill and WNBA Team Up for Groundbreaking Partnership
Rhea-AI Summary
Perrigo Company plc partners with WNBA to promote reproductive health through Opill®, the first daily birth control pill available without a prescription in the U.S., aiming to redefine contraception accessibility and empower women.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
partnership
-
News
Perrigo Commences Shipments of Opill® to Retailers Nationwide, Empowering Millions to Enter a New Era of Reproductive Health Access in the United States
Rhea-AI Summary
Perrigo Company plc (PRGO) announces the availability of Opill®, the first daily birth control pill without a prescription in the U.S., for pre-order and in-store purchase at major retailers nationwide. Opill® is FDA-approved and priced at $19.99 for one-month and $49.99 for three-month packs. It aims to address barriers to contraceptive access and is 98% effective. Opill® is a significant advancement in reproductive health, offering a convenient and affordable option for preventing unintended pregnancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
none
-
News
Perrigo to Attend UBS Global Consumer and Retail Conference
Rhea-AI Summary
Perrigo Company plc (NYSE: PRGO) to present at UBS Global Consumer and Retail Conference. President and CEO, Patrick Lockwood-Taylor, and CFO, Eduardo Bezerra, to speak on March 13th. Webcast available on Perrigo's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
conferences
News
Perrigo Reports Fourth Quarter & Fiscal Year 2023 Financial Results From Continuing Operations; Launches Investment & Efficiency Program
Rhea-AI Summary
Perrigo Company plc (PRGO) achieved record net sales in the fourth quarter and fiscal year 2023, with improvements in gross profit, operating income, and EPS. The company launched 'Project Energize' to drive sustainable growth. Despite challenges in organic net sales, the company reported positive results and outlined future outlooks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.14%
Tags
earnings
-
News
Perrigo Increases its Quarterly Dividend
Rhea-AI Summary
Perrigo Company plc (NYSE: PRGO) increases its quarterly dividend by 1% to $0.276 per share, marking the 21st consecutive year of dividend growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.14%
Tags
dividends
-
News
Perrigo to Release Fourth Quarter and Fiscal Year 2023 Financial Results on February 27, 2024
Rhea-AI Summary
Perrigo Company plc (PRGO) is set to release its fourth quarter and fiscal year 2023 financial results on February 27th, 2024. The earnings conference call will be accessible via webcast or phone, with a replay available until March 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
earnings
News
Perrigo Announces Early Results of Cash Tender Offer for Notes
Rhea-AI Summary
Perrigo Company plc (NYSE: PRGO) announced the early tender results of its cash tender offer to purchase its 3.900% Senior Notes due 2024 in a principal amount of up to $300,000,000. The total principal amount of Notes validly tendered and not withdrawn as of the Early Tender Date is $385,548,000, representing 42.86% of the outstanding principal amount. The Tender Offer will expire on December 12, 2023, with settlement expected on December 15, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
none
-
News
Perrigo Announces Cash Tender Offer for Notes
Rhea-AI Summary
Perrigo Company plc (NYSE: PRGO) Announces Commencement of Cash Tender Offer for Its 3.900% Senior Notes due 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
none
-
News
Perrigo Reports Third Quarter Fiscal Year 2023 Financial Results From Continuing Operations
Rhea-AI Summary
Perrigo Company plc (PRGO) reported a third-quarter net sales increase of 2.2% to $1.1 billion, with organic net sales decreasing 1.2%. The company achieved a gross margin of 36.6% and an adjusted gross margin of 39.5%. Reported EPS was $0.11, compared to a loss of $(0.39) in the prior year quarter. The company updates its fiscal 2023 organic net sales and total net sales growth outlook range to 1.0%-3.0% and 4.0%-6.0%, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.04%
Tags
earnings
News
Perrigo Announces Quarterly Dividend
Rhea-AI Summary
Perrigo Company plc (NYSE: PRGO) has declared a quarterly dividend of $0.273 per share. The dividend will be payable on December 19, 2023, to shareholders of record on December 1, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
dividends
Stock PRGO logo
Perrigo Company plc

NYSE:PRGO

PRGO Rankings

#1301 Ranked by Market Cap
#4007 Ranked by Stock Gains
#971 Ranked by Dividends

PRGO Stock Data

4.11B
134.68M
0.31%
99.54%
2.85%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Ireland
Dublin

About PRGO

perrigo company plc, a top five global over-the-counter (otc) consumer goods and pharmaceutical company, offers consumers and customers high quality products at affordable prices. from its beginnings in 1887 as a packager of generic home remedies, perrigo, headquartered in ireland, has grown to become the world's largest manufacturer of otc products and supplier of infant formulas for the store brand market. the company is also a leading provider of branded otc products, generic extended topical prescription products and receives royalties from multiple sclerosis drug tysabri®. perrigo provides “quality affordable healthcare products®” across a wide variety of product categories and geographies primarily in north america, europe, and australia, as well as other key markets including israel and china. visit perrigo online at (http://www.perrigo.com).